Helix BioPharma (TSE:HBP) Sets New 1-Year Low – What’s Next?

Helix BioPharma Corp. (TSE:HBP)’s share price hit a new 52-week low during mid-day trading on Wednesday . The stock traded as low as C$0.56 and last traded at C$0.58, with a volume of 20125 shares traded. The stock had previously closed at C$0.71.

Helix BioPharma Stock Performance

The company has a debt-to-equity ratio of 773.67, a current ratio of 0.74 and a quick ratio of 1.04. The company has a market cap of C$27.94 million, a price-to-earnings ratio of -3.55 and a beta of -0.84. The stock has a 50-day moving average price of C$1.15 and a 200 day moving average price of C$0.60.

Helix BioPharma Company Profile

Helix BioPharma Corp. operates as an immune-oncology company in Canada. It is developing L-DOS47 for the treatment of non-small cell lung cancer; and V-DOS47 that targets the vascular epithelial growth factor receptor 2. Helix BioPharma Corp. has collaboration agreements with Moffitt Cancer Center to investigate the pharmacodynamics of L-DOS47 and determine the benefits of combining L-DOS47 with immune checkpoint inhibitors; and with University Hospital Tuebingen to assess the therapeutic response of L-DOS47 in cancer models expressing CEACAM6, with advanced preclinical metabolic imaging.